These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 429575)
1. Determination of antithrombin activity by an amidolytic and a clotting procedure. Frigola A; Angeloni S; Cerqueti AR J Clin Pathol; 1979 Jan; 32(1):21-5. PubMed ID: 429575 [TBL] [Abstract][Full Text] [Related]
2. A simple amidolytic method for the determination of functional active antithrombin III. Abildaard U; Lie M; Odegård OR Scand J Clin Lab Invest; 1976 Jan; 36(1):109-12. PubMed ID: 815998 [TBL] [Abstract][Full Text] [Related]
3. The amidolytic activity of the SK-plasminogen complex is enhanced by a potentiator which is generated in the presence of vascular plasminogen activator--role of fibrin degradation products. Soria J; Soria C; Bertrand O; Dunn F; Samama M; Bachmann F Thromb Haemost; 1982 Jun; 47(3):193-6. PubMed ID: 7051407 [TBL] [Abstract][Full Text] [Related]
4. Heparin cofactor activity measured with an amidolytic method. Odegard OR; Lie M; Abildgaard U Thromb Res; 1975 Apr; 6(4):287-94. PubMed ID: 49087 [No Abstract] [Full Text] [Related]
5. Comparison of three methods for the estimation of plasma antithrombin. McLellan DS; Devlin JD; Heyse-Moore GH; Aronstam A J Clin Pathol; 1980 May; 33(5):438-44. PubMed ID: 6772690 [TBL] [Abstract][Full Text] [Related]
6. Reliability of amidolytic assays for progressive antithrombin and heparin cofactor activities on capillary blood. Hurlet-Birk Jensen A; Maes E; Gillet C; Legrand-Monsieur A Thromb Haemost; 1980 Jun; 43(2):104-7. PubMed ID: 7455966 [TBL] [Abstract][Full Text] [Related]
7. [Effects of alpha2-macroglobulin and FDP on the antithrombin III assay system (author's transl)]. Yoshida N; Tachiya K; Moroi M; Matsuda M; Aoki N Nihon Ketsueki Gakkai Zasshi; 1977 Apr; 40(2):197-201. PubMed ID: 70144 [No Abstract] [Full Text] [Related]
8. [Reliability of reptilase and thrombin coagulase coagulation times for measurement of antithrombin VI activity with reference to immunoelectrophoretic characteristics of various fibrinogen and fibrin fission products]. Stürner KH; Holzhüter H; Ochs HG; Angelkort B; Muchietti F; Wenzel E Verh Dtsch Ges Inn Med; 1973; 79():1328-30. PubMed ID: 4790173 [No Abstract] [Full Text] [Related]
9. Impaired inactivation by antithrombin and hirudin and preserved fibrinogen-clotting activity of thrombin in complex with anti-thrombin antibody from a patient with antiphospholipid syndrome. Kolev K; Léránt I; Skopál J; Kelemen A; Nagy Z; Machovich R Thromb Haemost; 2005 Jul; 94(1):82-7. PubMed ID: 16113788 [TBL] [Abstract][Full Text] [Related]
10. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195 [TBL] [Abstract][Full Text] [Related]
11. The anticoagulant effect of heparin + antithrombin III using purified fibrinogen as substrate. Andersen P; Godal HC Haemostasis; 1977; 6(6):329-38. PubMed ID: 611046 [TBL] [Abstract][Full Text] [Related]
12. Antifactor Xa activity measured with amidolytic methods. Odegård OR; Lie M; Abildgaard U Haemostasis; 1976; 5(5):265-75. PubMed ID: 1017722 [TBL] [Abstract][Full Text] [Related]
13. Abnormal antithrombin III (antithrombin III "Budapest") as a cause of a familial thrombophilia. Sas G; Blaskó G; Bánhegyi D; Jákó J; Pálos LA Thromb Diath Haemorrh; 1974 Sep; 32(1):105-15. PubMed ID: 4454033 [TBL] [Abstract][Full Text] [Related]
14. A method of antithrombin estimation using plasma defibrinates with ancrod. Howie PW; Prentice CR; McNicol GP Br J Haematol; 1973 Jul; 25(1):101-10. PubMed ID: 4799764 [No Abstract] [Full Text] [Related]
15. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation]. Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289 [TBL] [Abstract][Full Text] [Related]
16. [Determination of antithrombin III (chromogenic substrates) and FDP in women in treatment with oral estroprogestin agents]. Gibelli A; Giarola P; Ghessi A; Rocchini PM Minerva Med; 1978 Apr; 69(18):1241-4. PubMed ID: 662152 [TBL] [Abstract][Full Text] [Related]
17. Automated amidolytic method for evaluating the activated partial thromboplastin time compared with a conventional coagulation method. Tripodi A; Poggio M; Scapellato L; Mannucci PM Haemostasis; 1989; 19(4):205-12. PubMed ID: 2509308 [TBL] [Abstract][Full Text] [Related]
18. Human antithrombin concentrates and experimental disseminated intravascular coagulation. Mammen EF; Miyakawa T; Phillips TF; Assarian GS; Brown JM; Murano G Semin Thromb Hemost; 1985 Oct; 11(4):373-83. PubMed ID: 4071063 [TBL] [Abstract][Full Text] [Related]
19. Is it acceptable to use coagulation plasma samples stored at room temperature and 4°C for 24 hours for additional prothrombin time, activated partial thromboplastin time, fibrinogen, antithrombin, and D-dimer testing? Rimac V; Coen Herak D Int J Lab Hematol; 2017 Oct; 39(5):475-481. PubMed ID: 28488785 [TBL] [Abstract][Full Text] [Related]
20. Standardisation of a simple method for the determination of antithrombin activity. Frigola A J Clin Pathol; 1977 Sep; 30(9):881-3. PubMed ID: 915017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]